Brief: Alpha Tau Announces Receipt Of Radioactive License To Allow Production In Main Manufacturing Floor At Its Jerusalem Site, Amended Radioactive License With Increased Capacity At Lawrence, Ma Site
16/06/2022 21:31
June 16 (Reuters) - Alpha Tau Medical Ltd DRTS.O :
* ALPHA TAU ANNOUNCES RECEIPT OF RADIOACTIVE LICENSE TO
ALLOW
PRODUCTION IN MAIN MANUFACTURING FLOOR AT ITS JERUSALEM SITE,
AMENDED RADIOACTIVE LICENSE WITH INCREASED CAPACITY AT LAWRENCE,
MA SITE
Source text for Eikon: ID:nPn8FP2z8a
Further company coverage: DRTS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alpha Tau Medical
See all newsBrief: Alpha Tau Completes Patient Enrollment In Its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal Of FDA Approval Of Alpha Dart® To Treat Recurrent Cutaneous Squamous Cell Carcinoma
Brief: Alpha Tau Announces 100% Local Disease Control Rate And Favorable Safety Profile Observed In Alpha Dart® Pancreatic Cancer Trials Presented At Ddw 2026
Brief: Alpha Tau Medical Files To Offer Up To $300 Million In Securities - SEC Filing
Brief: Alpha Tau Announces First-Ever Oral Presentation Of Alpha Dart® Pancreatic Cancer Data At Digestive Disease Week (Ddw) 2026
Brief: Alpha Tau Medical Receives Japanese Marketing Approval For Alpha Dart In Head And Neck Cancer